However, it is reported that >50% patients with high PD-L1 expression in tumor tissue do not benefit from first-line Pembrolizumab [172], and 10% of patients with a PD-L1 negative tumor do respond to second-line inhibitors [173]. This evidence concerns the gene CD274 and neoplasm.